CAR T-cell therapy for certain blood cancers after relapse
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these diagnoses: B-cell ALL (age 25 or younger), DLBCL (age 18–70), or PMBCL (age 18–70)
- Your cancer has come back or did not respond after two prior treatment lines
- Your overall health is good enough that you have a performance status score of 0 or 1 (rather than worse)
- You do not have uncontrolled or active infections, and you have enough organ function for treatment
- You have not had a blood clot that affected circulation within the last 6 months
- You likely have at least 3 months of life expectancy and no major health problems that could be worsened by immunosuppressing treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This trial tests a locally made CAR T-cell therapy that targets CD19 on cancer cells. It is for children and young adults with certain B-cell cancers that have come back or not responded to other treatments.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Hear when a new Primary Mediastinal Large B-cell Lymphoma (PMBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.